Huna
Pre-Seed
Huna uses AI to analyze routine blood tests for early cancer detection.
Founded
2022Huna uses AI to analyze routine blood tests for early cancer detection.
Huna's AI platform analyzes routine complete blood count (CBC) data to assess cancer risk before symptoms appear. The platform classifies cancer risk in real-time across five types, starting with breast cancer and expanding to cervical, lung, colorectal, and prostate cancer.
The system can operate independently or integrate via API into existing healthcare workflows. It is designed for healthcare providers, laboratories, hospitals, pharmaceutical companies, insurers, and governments. The non-invasive approach enables mass screening at a fraction of the cost of traditional diagnostics such as mammography.
In Latin America, 80% of cancer cases are detected at advanced stages due to lack of access to early screenings. Huna addresses this gap by transforming routine blood tests into scalable cancer screening tools, starting in Brazil and expanding across the region.
The company's long-term vision includes supporting the full cancer care journey from early detection to personalized treatment, with AI that helps prioritize biopsies, predict recurrence, and optimize therapies. A pilot with Brazil's public health system in the Northeast region is bringing Huna's technology to 100,000 patients, demonstrating potential for population-scale impact.
Huna leverages ubiquitous and low-cost routine blood tests rather than expensive specialized diagnostics, making early cancer screening accessible to populations that cannot afford or access mammography and other traditional tools. The platform has analyzed over one million data points and demonstrated up to a 40% reduction in mortality from early diagnosis.
The company's peer-reviewed research published in Nature Scientific Reports provides clinical credibility that differentiates it from unvalidated health AI tools. Partnerships with leading Brazilian institutions including Hospital de Amor and Grupo Fleury provide real-world validation and distribution channels.